• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Providers
    • Hospitals
    • Practices
    • Retail
  • Health Tech
    • AI and Machine Learning
    • Digital Health
    • Telehealth
  • Payers
  • Regulatory
  • Finance
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • DEI Awards
    • Innovation Awards
  • Resources
    • Webinars
    • Fierce Events
    • Industry Events
    • Podcasts
    • Survey
    • Whitepapers
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Providers
    • Hospitals
    • Practices
    • Retail
  • Health Tech
    • AI and Machine Learning
    • Digital Health
    • Telehealth
  • Payers
  • Regulatory
  • Finance
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • DEI Awards
    • Innovation Awards
  • Resources
    • Webinars
    • Fierce Events
    • Industry Events
    • Podcasts
    • Survey
    • Whitepapers
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

patient affordability

Gene Therapy of treatment and adjustment of DNA
Payers

Insurers question cell and gene therapy costs as new model nears

Health plans and employers view gene therapy affordability as a challenge, as the CMS rolls out a sickle cell model to improve cost outcomes.
Noah Tong May 5, 2025 4:00pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
    • Editorial Advisory Council
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings